Stanford researchers have discovered RNA signatures that can be used to predict patient outcomes and identify optimal treatments in acute myeloid leukemia.
Stanford researchers have developed a new, low-cost method for tumor methylation profiling that enables tumor classification even from low amounts of fragmented DNA characteristic of liquid biopsies.
Liquid biopsies have emerged as a groundbreaking approach in cancer diagnostics, enabling the detection of DNA shed by cancer cells through a simple blood test. However, cancer cells also shed RNA into the blood.